Durvalumab Immunotherapy
Durvalumab Immunotherapy
About this item
Full title
Author / Creator
Publisher
Pittsburgh: Oncology Nursing Society
Journal title
Language
English
Formats
Publication information
Publisher
Pittsburgh: Oncology Nursing Society
Subjects
More information
Scope and Contents
Contents
Background: When resection is not an option, platinum-based chemoradiotherapy (CRT) has been the historic standard of care in non-small cell lung cancer (NSCLC). Prognosis remains poor with CRT alone. Durvalumab has shown significant improvement (versus placebo) in progression-free and overall survival in patients with unresectable stage III NSCLC...
Alternative Titles
Full title
Durvalumab Immunotherapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2412999716
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2412999716
Other Identifiers
ISSN
1092-1095
E-ISSN
1538-067X
DOI
10.1188/20.CJON.277-283
